MedTrace Logo

A Study for Evaluation of GSK Biologicals' Pandemic Influenza Vaccine

NCT00866580 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2015-03-23

No results posted yet for this study

Summary

This observer-blind study is designed to evaluate the immune response and safety of pandemic influenza vaccine in the elderly population.

Conditions

Interventions

BIOLOGICAL

GSK's candidate influenza vaccine 1562902A

Intramuscular dose on Day 0 and Day 21

BIOLOGICAL

FluarixTM

Intramuscular dose on Day 42 or on Day -30, according to the vaccination schedule

BIOLOGICAL

Placebo

Intramuscular dose on Day 42 or on Day -30, according to the vaccination schedule

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
61 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • Brazil

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00866580 on ClinicalTrials.gov